In the realm of cancer vaccines, neoantigen-based mRNA vaccines offer several additional advantages: (a) a single mRNA can incorporate multiple distinct neoantigens, thereby increasing the vaccine’s breadth and potency; (b) mRNAs can encode full-length or long-kmer neoantigen, containing multiple neoepitopes without MHC-restriction. Here, HLA-C is linked to cancer.